hotspot -WSS

hotspot

author：focus 2025-10-01 17:34:48 - browse：32

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Alabama hospital puts IVF treatments on hold

WSS

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

With competition flaring, obesity drug hits goal in liver disease study

FTC sues over Novant Health acquisition of two N.C. hospitals

White House pharmacy plagued with problems, investigation finds

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Alabama hospital puts IVF treatments on hold

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Moonlake's readout produced a cash windfall. Risks remain

How generative AI ratchets up security threats for health systems

Supreme Court strikes down use of affirmative action

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Medical records are filled with copy

FTC sues over Novant Health acquisition of two N.C. hospitals

State Dept. review finds Biden bears some blame for Afghanistan failures

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Moonlake's readout produced a cash windfall. Risks remain

Wegovy leads to weight loss. Can it treat depression, too?

explore

Alabama frozen embryo ruling has major implications for IVF clinics

The Harvard botanist who searched for psychedelics in the Amazon

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Alabama IVF ruling threatens families facing fatal genetic disease

How generative AI ratchets up security threats for health systems

Alabama frozen embryo ruling has major implications for IVF clinics

explore

hotspot

Wikipedia

knowledge